(MedPage Today) -- As medical organizations, lawmakers, advocates -- and even the lead actor from "The Pitt" -- laud the reauthorization of the Lorna Breen Act through fiscal year 2030, they're also urging millions of dollars to boost funding...
(MedPage Today) -- Rep. Lori Trahan (D-Mass.) during a House hearing on Tuesday expressed her frustration with HHS Secretary Robert F. Kennedy Jr., noting that he "managed to give a 'Go Gators' from the witness table, but not a 'Go [vitamin] K...
(MedPage Today) -- At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products...
(MedPage Today) -- SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients with advanced non-small cell lung cancer (NSCLC) with and without previous exposure to other KRAS G12C...
(MedPage Today) -- The Trump administration will require all 50 states to explain their plans to revalidate some of their Medicaid providers in a national escalation of anti-fraud efforts that have so far largely focused on specific states, Mehmet...
(MedPage Today) -- Real-world data suggested the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater weight loss, but also muscle loss, compared with semaglutide (Ozempic, Wegovy), according to a medical...
Should their merger close, the American Foundation for Suicide Prevention and The Jed Foundation would have an annual operating budget of about $75 million and net assets of around $140 million.
ECRI, a nonprofit healthcare quality and safety organization, spun out its spend management and recall management solutions an independent company backed by a strategic growth investment from Accel-KKR.
The administration's second stab at a rebate program for statutory drug discounts drew familiar arguments and new alarm bells over a potential expansion from last year's aborted iteration of the pharma-friendly pilot program.